Delsie Braganza

Delsie joined the Focal Point Research team in 2011 and has been an invaluable asset for our clients. With her strong regulatory and quality assurance background, she is able to help clients understand the Canadian and US requirements, set targets to achieve compliance, and attain their goals to get products to market.

Delsie is able to audit facilities, set up and maintain GMP compliant facilities, develop strong quality management systems, and co-ordinate successful Health Canada inspections. In addition to this, Delsie oversees all regulatory compliance reviews and submissions made to Health Canada and the US FDA.

Delsie obtained an Honours Bachelor of Science (Hons. B. Sc.) in Pharmaceutical Chemistry from the University of Toronto, Post-Graduate Certificate in Pharmaceutical Regulatory Affairs and Quality Operations (RAQ) from Seneca College and Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society (RAPS).

When she’s not learning something new, Delsie loves spending time with family, going on road trips or long walks, and swimming.

Articles

If you would like to be added to our newsletter, please send an email to mail@focalpointresearch.net with the subject line ‘Receive FPR Newsletter’.

NNHPD Updates NHPID entries due to Benzene risk

Apr 2, 2026

Following alerts from the US FDA regarding benzene contamination, the NNHPD has updated several entries in the NHPID. Benzene is a Class 1 solvent with unacceptable toxicity and must not be used in health product manufacturing. Key changes include the removal of...

Health Canada updates guidance on Adverse Reaction Reporting

Apr 2, 2026

Health Canada has issued a notice clarifying adverse reaction reporting expectations for Market Authorization Holders (MAHs) of drugs (including pharmaceuticals, biologics and radiopharmaceuticals) and Natural Health Products (NHPs). The notice replaces Section 4.3 of...

Health Canada modernizes Medical Device Submission Requirements

Apr 2, 2026

Health Canada has introduced several key regulatory updates in 2026 that significantly change how medical device applications are prepared and submitted. A major update is the new Guidance on Managing Applications for Medical Device Licenses (effective February 2,...

New Compliance Requirements for the Canadian Domestic Substance List (DSL)

Apr 2, 2026

On March 25, 2026, the Government of Canada published Order 2026-87-20-01 in the Canada Gazette, Part II. This order introduces significant amendments to the Domestic Substance List (DSL) under the Canadian Environmental Protection Act (CEPA). The changes impact...

Health Canada ends FSRN Process

Feb 24, 2026

A Foreign Site Reference Number (FSRN) is generally issued by Health Canada to foreign sites that manufacture, package, or label Natural Health Products (NHPs). It confirms partial compliance with GMP requirements under Part 3 of the NHP regulations. A FSRN is not...

New FDA Draft Guidance: Records Access for Cosmetics Under MoCRA

Feb 13, 2026

The U.S. Food and Drug Administration (FDA) has released a new draft guidance titled ‘Records Access for Cosmetics’. This publication marks another step in the ongoing implementation of the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Purpose and Scope:...

Arizona Introduces SB 1005 to Ban Cosmetic Animal Testing

Feb 13, 2026

The landscape of cosmetic regulation in the United States continues to evolve. The Arizona State Senate has officially introduced SB 1005, a bill that seeks to prohibit the use of animal testing for cosmetic products within the state. If enacted, this legislation...

California DTSC Finalizes MMA Regulation for Nail Products

Feb 13, 2026

The California Department of Toxic Substances Control (DTSC) has officially finalized new regulations under the Safer Consumer Products (SCP) program, targeting methyl methacrylate (MMA) in nail products. If your company manufactures nail coatings or artificial nails...

FDA Announces Fiscal Year 2026 OMOR Fee Rates: Costs to Increase

Feb 13, 2026

The U.S. Food and Drug Administration (FDA) has officially released the fee rates for Over-the-Counter (OTC) Monograph Order Requests (OMOR) for the upcoming Fiscal Year (FY) 2026. As the OTC landscape continues to evolve under the CARES Act reforms, manufacturers and...

FDA Releases Draft Guidance on Mandatory Cosmetics Recalls under MoCRA

Feb 13, 2026

The U.S. Food and Drug Administration (FDA) has published a significant new draft guidance document titled ‘Questions and Answers Regarding Mandatory Cosmetics Recalls: Guidance for Industry.’ This release is a key step in implementing the Modernization of Cosmetics...

« Older Entries

Next Entries »

“Focal Point Research has consistently and professionally looked after regulatory and quality issues of our brand for years. Through a courteous and knowledgeable team, they have managed to navigate us through an ever changing regulatory landscape while maintaining our interests, and allowed us to correctly distribute and sell within Canada.”

“I have truly enjoyed working with you over the last 8 years! You and your team have been an amazing resource for me. I have always been impressed by the knowledge and professionalism of everyone at Focal Point, which is a true testament to your leadership.”

Connect With Us

The Focal Point Research team is ready to help with all of your scientific and regulatory needs. Our team has the experience and expertise you need to see your product to market and we are eager to help you.

Focal Point Research Inc.

6700 Century Ave., Suite 319

Mississauga, ON L5N 6A4

Delsie Braganza

Jennifer Porter, BA Psychology, MBA – President & CEO

Articles

If you would like to be added to our newsletter, please send an email to mail@focalpointresearch.net with the subject line ‘Receive FPR Newsletter’.

Connect With Us